Singapore - English - HSA (Health Sciences Authority)

b-com impact pte ltd - clinical chemistry - glucose-6-phosphate dehydrogenase reagents are for the qualitative and quantitative determination of g-6-pdh deficiency in blood.

United States - English - NLM (National Library of Medicine)

60 degrees pharmaceuticals, llc - tafenoquine (unii: 262p8gs9l9) (tafenoquine - unii:262p8gs9l9) - arakoda is indicated for the prophylaxis of malaria in patients aged 18 years and older. arakoda is contraindicated in: the use of arakoda during pregnancy may cause hemolytic anemia in a fetus who is g6pd-deficient. treatment with arakoda during pregnancy is not recommended. if a pregnancy is detected during arakoda use, discontinue arakoda as soon as possible and switch to an alternative prophylactic drug for malaria during pregnancy [see warnings and precautions (5.2)] . available data with use of arakoda in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal studies, there were increased abortions, with and without maternal toxicity when tafenoquine was given orally to pregnant rabbits at and above doses equivalent to about 0.4 times the clinical exposure based on body surface area comparisons. no fetotoxicity was observed at doses about 1.5 times the clinical exposure (based on body surface area compariso

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - glipizide - tablets - glipizide 5 mg - glipizide - glipizide - is indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with diabetes mellitus type ii

Israel - English - Ministry of Health

gsk consumer healthcare, israel ltd - acetylsalicylic acid; caffeine; paracetamol - caplets - paracetamol 250 mg; acetylsalicylic acid 250 mg; caffeine 65 mg - paracetamol, combinations excl. psycholeptics - paracetamol, combinations excl. psycholeptics - for temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.

European Union - English - EMA (European Medicines Agency)

crealta pharmaceuticals ireland limited - pegloticase - gout - antigout preparations - krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

European Union - English - EMA (European Medicines Agency)

provepharm sas - methylthioninium chloride - methemoglobinemia - all other therapeutic products - acute symptomatic treatment of medicinal and chemical products- induced methaemoglobinaemia.methylthioninium chloride proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old).

United States - English - NLM (National Library of Medicine)

stat rx usa llc - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. qualaquin oral capsules are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1) ]. qualaquin is contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.3) ]. - glucose-6-phosphate dehydrogenase (g6pd) deficiency. - hemolysis can occur in patients with g6pd deficiency receiving quinine. - known hypersensitivity reactions to quinine. these include, but are not li

United States - English - NLM (National Library of Medicine)

ar scientific inc. - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. qualaquin oral capsules are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1) ]. qualaquin is contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.3) ]. - glucose-6-phosphate dehydrogenase (g6pd) deficiency. - hemolysis can occur in patients with g6pd deficiency receiving quinine. - known hypersensitivity reactions to quinine. these include, but are

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - quinine sulfate capsule usp is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14)] . quinine sulfate capsules usp are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1)] . quinine sulfate is contraindicated in patients with the following:   •  prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.3)].   •  glucose-6-phosphate dehydrogenase (g6pd) deficiency.   •  hemolysis can occur in patients with g6pd deficiency receiving quinine.   •  known hypersensitivity reactions to quin

United States - English - NLM (National Library of Medicine)

horizon therapeutics usa, inc. - pegloticase (unii: r581ot55ea) (pegloticase - unii:r581ot55ea) - pegloticase 8 mg in 1 ml - krystexxa® (pegloticase) is indicated, for the treatment of chronic gout in adult patients refractory to conventional therapy. gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. limitations of use: krystexxa is not recommended for the treatment of asymptomatic hyperuricemia. krystexxa is contraindicated in: - patients with glucose-6-phosphate dehydrogenase (g6pd) deficiency [see warnings and precautions (5.3)] - patients with history of serious hypersensitivity reactions, including anaphylaxis, to krystexxa or any of its components risk summary there are no adequate and well-controlled studies of krystexxa in pregnant women. based on animal reproduction studies, no structural abnormalities were observed when pegloticase was administered by subcutaneous injection to pregnant rats and